OH2 Injection in Melanoma
A phase 3 trial of OH2 in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
Overview
OH2 Injection in Melanoma is a phase 3 interventional study registered as NCT05868707 by Binhui Biopharmaceutical Co., Ltd., with 340 participants planned, started 2023-03-08 and due to reach its primary completion in 2026-03. Interventions recorded: OH2 and Salvage chemotherapy or best supportive care.
Setting
To Evaluate a Phase III Study of OH2 Versus Investigator-selected Salvage Chemotherapy or Best Supportive Care in Melanoma Patients Who Had Failed Standard Therapy
Phase
Phase 3
Sponsor
Binhui Biopharmaceutical Co., Ltd.
Registry
Enrolled
340
Similar pages
not linked directly; found by shared links- TrialOH2 Oncolytic Viral Therapy in Solid Tumors
Shares Binhui Biopharmaceutical and the tag pipeline.
- TrialOH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Shares Binhui Biopharmaceutical and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialNeoadjuvant L19IL2/L19TNF- Pivotal Study
Shares Melanoma and the tag pipeline.
- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Melanoma and the tag pipeline.
- TrialAMT-253 in Patients With Advanced Solid Tumours
Shares Melanoma and the tag pipeline.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Melanoma and the tag pipeline.